Amgen's earnings call presents a positive outlook with strong financial performance, driven by growth in non-ESA products and international sales, despite challenges in the anemia segment. The highlight of the call is the promising data on denosumab, which has potential for significant market impact in osteoporosis and cancer. Management's tone is optimistic, reflected in increased revenue and EPS guidance for 2008. The combination of a solid financial quarter and positive clinical data are likely to have a favorable short-term impact on Amgenâ€™s stock price.

[1]